Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer
American journal of clinical oncology, v 41(11), pp 1125-1131
01 Nov 2018
PMID: 29509593
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction: A growing body of preclinical data suggests that statins may exert potent antitumor effects, yet the interactions of these medications with standard therapies and clinical outcomes in this population is less clear. We assessed the impact of statin use on outcomes in patients with advanced-stage pancreatic adenocarcinoma undergoing various treatments.
Materials and Methods: After institutional review board approval, we conducted a retrospective-cohort study consisting of 303 newly diagnosed advanced-stage pancreatic adenocarcinoma patients to determine the impact of statin use on outcomes. Univariate and multivariable Cox proportional hazard regression models were utilized to estimate hazard ratios (HRs). Time-to-event was estimated using Kaplan-Meier survival analysis for overall survival, distant metastasis, and locoregional failure. Baseline and active statin usage were assessed and to mitigate risk of immortal time bias, subanalysis excluding patients with under 6 months of follow-up was conducted.
Results: Both prior (P = 0.021) and active (P = 0.030) statin usage correlated with improved survival in this cohort. Surgery, chemoradiation, and statin use improved 2-year survival rates (84.1% vs. 55.0%; P < 0.001). On multivariable analysis, statin exposure was associated with overall survival (HR, 0.662; P = 0.027) and trended to significance for freedom from distant metastasis (HR, 0.577; P = 0.060). Comorbid conditions were not significantly associated with outcomes.
Conclusions: Statin use was associated with improved overall survival in advanced-stage pancreatic adenocarcinoma patients. This data supports previous findings in early-stage pancreatic adenocarcinoma and other cancer sites. To our knowledge this is the first report to examine the efficacy of statin use as a supplementary treatment option in advanced-stage pancreatic adenocarcinoma patients.
Metrics
Details
- Title
- Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer
- Creators
- Nick A. Iarrobino - University of PittsburghBeant Gill - University of Pittsburgh Medical CenterMark E. Bernard - University of KentuckyMark V. Mishra - University of Maryland, BaltimoreColin E. Champ - University of Pittsburgh Medical Center
- Publication Details
- American journal of clinical oncology, v 41(11), pp 1125-1131
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 7
- Grant note
- T35DK065521 / National Institute of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA T35DK065521 / NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000453924100015
- Scopus ID
- 2-s2.0-85055693636
- Other Identifier
- 991021897287004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology